☆ 4.7 Article

Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Chemistry, Medicinal

Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex

Dhanushka Weerakoon et al.

Summary: In this study, the conformational behavior of two PROTACs, MZ1 and dBET6, was investigated using molecular dynamics simulations. The simulations revealed different linker conformational behaviors and a tendency towards an intramolecular lipophilic interaction between the two warheads. The dissociation mechanism of the von Hippel-Lindau-MZ1-BRD4 complex was also studied and shown to follow a two-step pathway.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2022)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies

Xufen Yu et al.

Summary: In this study, we reported a potent AKT degrader MS21 and its structure-activity relationship (SAR) studies. Additionally, we discovered another VHL-recruiting AKT degrader MS143 with similar efficacy as MS21, as well as a novel CRBN-recruiting PROTAC MS5033. These compounds effectively degraded AKT by hijacking the ubiquitin-proteasome system and showed significant inhibition of cell growth in multiple cancer cell lines. Furthermore, they exhibited good plasma exposure levels in mice and were suitable for in vivo studies.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Chemistry, Medicinal

Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders

Xufen Yu et al.

Summary: AKT, a critical node in the PI3K/AKT/m-TOR signaling pathway, is strongly correlated with cancer. Two novel and potent AKT degraders were identified, showing the ability to induce AKT protein degradation and inhibit cancer cell proliferation.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Integrative Modeling of PROTAC-Mediated Ternary Complexes

Gaoqi Weng et al.

Summary: Proteolysis-targeting chimeras (PROTACs) represent an emerging drug discovery technology that selectively induce targeted protein degradation. PROTAC-Model, an integrative computational method, was developed to predict PROTAC-mediated ternary complex structures and showed better performance in rational design of PROTACs.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta

Nan Bai et al.

Summary: PROTACs are molecules that induce target protein degradation by combining a target-binding warhead with an E3 ligase-recruiting moiety. A structure-based computational method has been developed to evaluate the suitability of linkers for ternary complex formation, which can explain PROTACs' activity and selectivity. Modeling ternary complex formation can help interpret PROTAC activity and reveal different binding modes within structurally conserved protein families.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Transforming targeted cancer therapy with PROTACs: A forward-looking perspective

William Farnaby et al.

Summary: Small-molecule targeted protein degraders known as PROTACs have shown potential to broaden drug target scope, address drug resistance, enhance target selectivity, and provide tissue specificity in cancer therapy. However, further development and refinement are needed to fully realize the benefits of this approach.

CURRENT OPINION IN PHARMACOLOGY (2021)

添加到收藏夹

Review Chemistry, Medicinal

An updated patent review of Akt inhibitors (2016-present)

Yu Guo et al.

Summary: This review focuses on the patent literature covering small-molecule inhibitors of Akt kinase and their applications from 2016-present, indicating that although progress with Akt inhibitors has been slow, new strategies provide new opportunities for development. The combination of Akt inhibitors and immunotherapy may become a research hotspot in the future.

EXPERT OPINION ON THERAPEUTIC PATENTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Discovery and resistance mechanism of a selective CDK12 degrader

Baishan Jiang et al.

Summary: CDK12 is a promising therapeutic target for regulating DNA damage response genes transcription, but selective small molecule development has been hindered by its homology with other transcriptional CDKs. A CDK12-specific degrader, BSJ-4-116, was successfully designed and characterized, which selectively degraded CDK12 and resulted in premature cleavage and poly(adenylation) of DDR genes.

NATURE CHEMICAL BIOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?

Federica Martorana et al.

Summary: The AKT protein kinase is crucial in breast cancer treatment, especially in resistant subtypes. Several AKT inhibitors are in clinical trials, with new combination strategies being explored to enhance therapeutic efficacy.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras

Troy A. Bemis et al.

Summary: A current bottleneck in the development of PROTACs is the empirical nature of linker length structure-activity relationships. A multi-disciplinary approach has been detailed to alleviate this bottleneck. Research has focused on synthetic approaches to increase throughput, advances in structural biology and computational chemistry for rational PROTAC design, and de novo linker design in silico.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity

Jinxin Che et al.

Summary: Inhibiting Akt2 isozyme may lead to keratinocyte apoptosis, driving the search for new selective Akt inhibitors with improved cutaneous safety. After optimization, Hu7691 shows promising selectivity, low apoptosis induction in keratinocytes, and excellent anticancer cell proliferation potency, leading to its approval by NMPA for clinical trials.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Review Chemistry, Multidisciplinary

E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points

Alesa Bricelj et al.

Summary: PROTACs, as a new and exciting class of therapeutic agents, consist of target binding units, linkers, and E3 ligase binding moieties, leading to ubiquitination and proteasomal degradation of target proteins through the chemically-induced formation of ternary complexes. This review provides in-depth analysis on the synthetic preparation of functionalized ligands for relevant E3 ligases, highlighting the importance of understanding preparative routes and chemistry of linker attachment for the assembly of final PROTACs.

FRONTIERS IN CHEMISTRY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting PI3K/Akt signal transduction for cancer therapy

Yan He et al.

Summary: The PI3K/Akt signaling pathway plays a crucial role in cancer, and targeting inhibitors against it may aid in drug discovery. Additionally, combining pathway inhibitors with other cancer treatment strategies could be an effective approach to solving therapeutic dilemmas.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targeted degradation of the enhancer lysine acetyltransferases CBP and p300

Raghu Vannam et al.

Summary: The study presents a chemical degrader of p300/CBP, dCBP-1, designed by leveraging structures of ligand-bound p300/CBP through in silico modeling of ternary complex formation. It is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer driving oncogene expression. This efficient degrader provides a useful tool for dissecting the mechanism by which these factors coordinate enhancer activity in normal and diseased cells, alongside domain inhibitors.

CELL CHEMICAL BIOLOGY (2021)

添加到收藏夹

Article Biochemical Research Methods

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

Tasuku Ishida et al.

Summary: PROTACs, or bifunctional degrader molecules, are a novel approach for understanding and treating human diseases by targeting specific proteins for degradation. Advances in nonpeptidic small-molecule E3 ligase ligands, such as VHL and CRBN, have revolutionized the field and led to the development of drug-like PROTACs with powerful degradation capabilities. Ongoing research aims to expand the chemical diversity of PROTACs and explore new approaches for targeted protein degradation.

SLAS DISCOVERY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery

George M. Burslem et al.

CELL (2020)

添加到收藏夹

Review Oncology

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Xin Li et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Editorial Material Chemistry, Medicinal

Spotlight on AKT: Current Therapeutic Challenges

Ina Landel et al.

ACS MEDICINAL CHEMISTRY LETTERS (2020)

添加到收藏夹

Editorial Material Chemistry, Medicinal

PROTAC Technology: Opportunities and Challenges

Hongying Gao et al.

ACS MEDICINAL CHEMISTRY LETTERS (2020)

添加到收藏夹

Article Chemistry, Medicinal

Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation via New In Silico Methodologies

Michael L. Drummond et al.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling

Inchul You et al.

CELL CHEMICAL BIOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Development and Characterization of a Wee1 Kinase Degrader

Zhengnian Li et al.

CELL CHEMICAL BIOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

PROTACs: An Emerging Therapeutic Modality in Precision Medicine

Dhanusha A. Nalawansha et al.

CELL CHEMICAL BIOLOGY (2020)

添加到收藏夹

Review Oncology

The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism

Gerta Hoxhaj et al.

NATURE REVIEWS CANCER (2020)

添加到收藏夹

Article Chemistry, Medicinal

In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application

Michael L. Drummond et al.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2019)

添加到收藏夹

Article Oncology

Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes

Lu Zhang et al.

MOLECULAR CANCER THERAPEUTICS (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Protein Interaction Z Score Assessment (PIZSA): an empirical scoring scheme for evaluation of protein-protein interactions

Ankit A. Roy et al.

NUCLEIC ACIDS RESEARCH (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeted protein degradation: elements of PROTAC design

Stacey-Lynn Paiva et al.

CURRENT OPINION IN CHEMICAL BIOLOGY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design

Xiaowu Dong et al.

JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Meeting Abstract Hematology

Interaction of Mantle Cell Lymphoma with the Microenvironment Induces Phospho Akt-Mediated Resistance Against BTK Inhibition and Can be Overcome By Co-Treatment with a Specific Akt Inhibitor (MK-2206)

Elisabeth Silkenstedt et al.

BLOOD (2019)

添加到收藏夹

Article Chemistry, Medicinal

fDiscovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors

Wenhu Zhan et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting AKT for cancer therapy

Maryam Shariati et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Targeted protein degradation: expanding the toolbox

Matthieu Schapira et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Article Genetics & Heredity

Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome

Kim M. Keppler-Noreuil et al.

AMERICAN JOURNAL OF HUMAN GENETICS (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Plasticity in binding confers selectivity in ligand-induced protein degradation

Radoslaw P. Nowak et al.

NATURE CHEMICAL BIOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Delineating the role of cooperativity in the design of potent PROTACs for BTK

Adelajda Zorba et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Maximising the potential of MKT inhibitors as anti-cancer treatments

Jessica S. Brown et al.

PHARMACOLOGY & THERAPEUTICS (2017)

添加到收藏夹

Article Biochemical Research Methods

SynergyFinder: a web application for analyzing drug combination dose-response matrix data

Aleksandr Ianevski et al.

BIOINFORMATICS (2017)

添加到收藏夹

Article Hematology

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL

Tabea Erdmann et al.

BLOOD (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

AKT/PKB Signaling: Navigating the Network

Brendan D. Manning et al.

CELL (2017)

添加到收藏夹

Review Medicine, Research & Experimental

The PI3K/AKT Pathway as a Target for Cancer Treatment

Ingrid A. Mayer et al.

ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)

添加到收藏夹

Article Chemistry, Medicinal

Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors

Wenhu Zhan et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Jean-Marc Lapierre et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Degradation of Akt using protein-catalyzed capture agents

Ryan K. Henning et al.

JOURNAL OF PEPTIDE SCIENCE (2016)

添加到收藏夹

Article Oncology

Novel agents and associated toxicities of inhibitors of the PI3K/Akt/mTOR pathway for the treatment of breast cancer

S. Chia et al.

CURRENT ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer

Khanh Do et al.

INVESTIGATIONAL NEW DRUGS (2015)

添加到收藏夹

Letter Hematology

Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways

Xiaoxian Zhao et al.

BRITISH JOURNAL OF HAEMATOLOGY (2015)

添加到收藏夹

Article Chemistry, Medicinal

Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors

Wenhu Zhan et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)

添加到收藏夹

Article Chemistry, Medicinal

Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors

Tao Liu et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor

Melissa Dumble et al.

PLOS ONE (2014)

添加到收藏夹

Editorial Material Oncology

Lenalidomide induces degradation of IKZF1 and IKZF3

Jan Kroenke et al.

ONCOIMMUNOLOGY (2014)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases

Matt Addie et al.

JOURNAL OF MEDICINAL CHEMISTRY (2013)

添加到收藏夹

Article Medicine, General & Internal

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael L. Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors

James F. Blake et al.

JOURNAL OF MEDICINAL CHEMISTRY (2012)

添加到收藏夹

Article Chemistry, Medicinal

Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors

Xiaowu Dong et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)

添加到收藏夹

Review Chemistry, Medicinal

Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape

Margrith E. Mattmann et al.

EXPERT OPINION ON THERAPEUTIC PATENTS (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

Impact of linker length on the activity of PROTACs

Kedra Cyrus et al.

MOLECULAR BIOSYSTEMS (2011)

添加到收藏夹

Article Oncology

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

Hiroshi Hirai et al.

MOLECULAR CANCER THERAPEUTICS (2010)

添加到收藏夹

Article Hematology

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

Jessica Dal Col et al.

BLOOD (2008)

添加到收藏夹

Review Oncology

Deregulation of the Akt pathway in human cancer

Eriko Tokunaga et al.

CURRENT CANCER DRUG TARGETS (2008)

添加到收藏夹

Review Biochemistry & Molecular Biology

AKT/PKB signaling: Navigating downstream

Brendan D. Manning et al.

CELL (2007)

添加到收藏夹

Review Biochemistry & Molecular Biology

Perturbations of the AKT signaling pathway in human cancer

DA Altomare et al.

ONCOGENE (2005)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Akt/PKB pathway: molecular target for cancer drug discovery

JQ Cheng et al.

ONCOGENE (2005)

添加到收藏夹

Review Oncology

The phosphatidylinositol 3-kinase-AKT pathway in human cancer

I Vivanco et al.

NATURE REVIEWS CANCER (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.